CEO: Elisabet de los Pinos

Advent Contact: Raj Parekh

First pharmacological treatment for ocular melanoma

Aura is developing a first-in-class treatment for ocular melanoma and other ocular cancers based on a photo-activatable dye conjugated to HPV-derived nanoparticles that target tumour cells in the eye. Aura's lead product will enter clinical testing in early 2017. It is potentially the first alternative to the current treatment options of either radiotherapy or enucleation.

Advent invested in the Series B in 2015.